Do you want to learn more about marketing, content, comms & brand narrative?

Sign up to our monthly newsletter

Marketing, Strategy

Marketing Messaging: the critical (and silent) framework in biotech success

23/03/2026
|

In the fast-paced world of biotech discovery and product development, a lot of effort goes into meeting product requirements, generating data to match key specs, and hitting regulatory milestones. In my seven years working in (or for) biotech, I’ve spent over 4,000 hours in meetings… a staggering investment of time. Yet, looking back, it is striking how rarely senior contributors and managers sat down to discuss marketing messaging.

In life sciences, it is common to mistake the “what” of our science for the “why” of our business. As Pierre Herubel, a leader in B2B content strategy, often points out: “If everyone says they are ‘innovative,’ then no one is.” In biotech, where stakes are high and the audience is inherently skeptical, a lack of clear messaging doesn’t just cost you a click, it costs you your hard-earned credibility.

Defining the critical framework: beyond buzzwords

Messaging is the strategic use of words, tone, and narrative to create a consistent framework for how a company speaks. It is the connective tissue between your permanent branding (the foundational “soul” and mission) and your tactical or campaign slogans (the temporary external “hooks”).

To move beyond “science-speak” and achieve true persuasion, we must adopt a “demand creation” mindset. This means our messaging shouldn’t just capture existing interest; it should educate the market on why a problem exists and why our solution is the definitive answer. This blueprint is built on four essential ingredients.

1. The Value Proposition: moving from “what” to “so what?”

A compelling value proposition must answer why a customer should choose your product over every other option. Peep Laja, founder of CXL and Wynter (and B2B Marketing expert), argues that a UVP (Unique Value Proposition) is the number 1 thing that determines if someone stays on your page or hits “back.”

In biotech, this means moving past a list of technical specifications to explain the outcomes and the specific value that your solution brings. It is about promising a transformed future state (e.g., eliminating experimental variability through automation or reducing clinical trial timelines by 30%) rather than just describing a mechanism of action. If your value proposition doesn’t highlight a clear technological, clinical or economic moat, it is likely being ignored.

2. The Target Audience: segmenting for “message-market fit”

Effective messaging requires a radical focus on your target personas. You must understand exactly who they are and the specific words they use in their daily work. In B2B, you aren’t selling to a company; you’re selling to a person with a job title, and specific pains and metrics they are measured on.

A Lab Manager and a Venture Capitalist have vastly different “jobs to be done.” One cares about throughput and reliability; the other looks for risk mitigation and a clear path to commercialization. By identifying the specific “proof” each persona needs, you can tailor your narrative to meet them exactly where they are in their buyer’s journey.

3. Tone of Voice: the personality of the science

    Your brand needs a “common voice” to build a recognizable identity. This involves choosing a brand persona and a set of keywords that match your identity, whether that is “authoritative and empathic” or “disruptive and challenge-led.”

    While your brand’s core personality remains the same, your tone must be flexible depending on the channel you use. It won’t be the same for short social media posts as for technical white papers. Your voice stays the same, but the tone shifts from the punchy, provocative style of a LinkedIn post to the rigorous, evidence-based analysis of a technical brief. This consistency builds “mental availability,” ensuring your brand is the first one thought of when a need arises or during a buying situation.

    4. Messaging Pillars: moving to “1% insights”

    Finally, you must select your messaging pillars, ideally three main themes that act as the “north star” for your content. Most biotech companies share basic truths that everyone repeats. To truly stand out, your pillars should be built on “strategic” or “1% insights”: rare, perspective-changing lessons earned through deep industry experience. And truly embracing Thought Leadership (visit our Toolkit for a full guide!).

    These pillars ensure that your messaging remains genuine and aligned with your brand identity at every touchpoint. They ensure that when you’ve spent your 4,000th hour in a meeting, the team is still aligned on the same three core arguments that convince your audience of your authority.

    Since you’re here, make sure to subscribe to our newsletter, (Your) Messaging Matters, for more deep dives into life science marketing and communications

    .

    Consistency as a competitive advantage

    Refining this framework requires iteration, but consistency is the ultimate goal. When your internal teams and external communications are in perfect sync, you move from merely providing information to creating conviction. Your target audience’s trust will increase over time after your content shows the key identifiable “traits” from your brand and offering.

    At ACBio, we help biotech companies turn complex data into persuasive, “authority-first” narratives.

    Do you need help refining your messaging? If you’re ready to turn your 4,000 hours of meetings into a clear, strategic voice:

    Drop us a message to discuss your current framework!

    Anna Caballe

    Anna Caballe

    Anna founded ACBio to make life science innovations technically understandable, impactful, and valued by customers, partners, investors, healthcare professionals, and the public. Throughout her research career (PhD at King's College London and postdoc at University of Oxford), Anna investigated crucial molecular and cellular mechanisms of cell division, viral particle release, and endocytosis. She combined her research with science communication, writing for different outlets and magazines. Between 2019 and 2024, Anna worked in UK biotech (Oxford Nanoimaging, ONI), developing key skills in marketing, product management, business development, and content strategy, and deep knowledge of microscopy and nanobiotechnology (EVs and LNPs). In September 2024, Anna founded ACBio in Switzerland to help biotech, CSOs, and biopharma companies globally.

    Do you want to learn more about marketing, content, comms & brand narrative?

    Sign up to our monthly newsletter

    Scroll to Top